Fulcrum falls after discontinuing sickle cell drug program
BUZZ-Fulcrum falls after discontinuing sickle cell drug program ** Shares of drug developer Fulcrum Therapeutics FULC.O fall 49.7% to $3.23 premarket
** Co said late on Monday it is discontinuing development of its experimental pociredir program for the treatment of sickle cell disease, an inherited blood disorder
** Fulcrum said that FDA had expressed concerns tied to secondary blood cancers seen with Ipsen's IPN.PA cancer drug, Tazverik, which was withdrawn globally in March
** The company said it submitted information to the FDA supporting the position that mechanistic differences between the two drugs' target were relevant to the benefit-risk assessment
** The FDA, however, concluded that any drug that targets the protein PRC2 carries risk
** Fulcrum will explore options including a merger, acquisition, business combination or other transaction, and has initiated efforts to cut operating expenses and preserve cash
** Up to last close, stock down 43% YTD
(Reporting by Siddhi Mahatole)
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients